Asia – Page 8 – pharmaceutical daily

July 18, 2019 Off

Inflection Biosciences and AUM Biosciences Announce Global License Agreement for PIM/PI3K/mTOR Inhibitors

Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of cancer, and AUM Biosciences (AUM), a company focused on the development of innovative and affordable oncology medicines with high unmet medical need in Asia, today announced a global license agreement for Inflection’s first-in-class PIM/PI3K/mTOR inhibitors.

July 17, 2019 Off

AUM Biosciences Expands Pipeline With Global License for First-in-class Targeted Cancer Therapy

By BusinessWire

Second major acquisition sets Singapore headquartered company on course to uniquely drive global therapeutic innovation from Asia SINGAPORE–(BUSINESS WIRE)–AUM Biosciences…

July 5, 2019 Off

ACT Genomics Opens Third Laboratory in Asia at Hong Kong Science Park

By BusinessWire

Strives to Change the Cancer Treatment Model in Hong Kong Ready to Tap Tremendous Opportunities in Greater Bay Area HONG…

July 3, 2019 Off

Takeda to Demonstrate Global Leadership in Hematology at ISTH 2019

By BusinessWire

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”), the global biotechnology leader in rare diseases, will present research covering a broad range of rare bleeding disorders at the 27th Annual International Society on Thrombosis and Haemostasis Congress

July 2, 2019 Off

Takeda Completes Sale of Xiidra to Novartis

By BusinessWire

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its sale of its Xiidra® (lifitegrast ophthalmic solution) 5% product to Novartis for $3.4 billion upfront in cash and up to an additional $1.9 billion in potential milestone payments.

June 28, 2019 Off

Glenmark Pharmaceuticals granted Ezetimibe, Simvastatin tablets in USA

By Dino Mustafić

Indian Glenmark Pharmaceuticals has been granted final approval by the U.S. FDA for Ezetimibe and Simvastatin Tablets, for several doses.

June 25, 2019 Off

Dr. Reddy’s Laboratories launches Tobramycin Inhalation Solution, USP in the U.S. market

By BusinessWire

Dr. Reddy’s is launching Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI

June 25, 2019 Off

Poxel, Sumitomo Dainippon Pharma’s Type 2 Diabetes combo imeglimin/insulin Phase 3 trial meets primary endpoint

By BusinessWire

Imeglimin in combination with insulin Phase 3 TIMES 3 16-week, double-blind, placebo-controlled, randomized part of the trial met its primary endpoint with a favorable safety and tolerability profile

June 24, 2019 Off

Terns Pharmaceuticals Announces Exclusive Licensing and Collaboration Agreement with GENFIT to Develop and Commercialize Elafibranor in the Greater China Region

By BusinessWire

-GENFIT partnership expands Terns’ portfolio, adding a Phase 3 product with a complementary mechanism of action well-suited to combinations with…

June 23, 2019 Off

Dr. Reddy’s Laboratories Announces the Launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules in the U.S. Market

By BusinessWire

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together…